Cargando…
Incretin-based therapies for patients with type 1 diabetes: a meta-analysis
OBJECTIVE: Combined treatment with an incretin-based drug, such as a glucagon-like peptide 1 receptor agonist (GLP-1 RA) or a dipeptidyl peptidase-4 (DPP-4) inhibitor, and basal insulin is a new strategy for improving glucose control in type 1 diabetes mellitus (T1DM). We performed a meta-analysis t...
Autores principales: | Liu, Lili, Shao, Zhuo, Xia, Ying, Qin, Jiabi, Xiao, Yang, Zhou, Zhiguang, Mei, Zubing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bioscientifica Ltd
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6410765/ https://www.ncbi.nlm.nih.gov/pubmed/30694794 http://dx.doi.org/10.1530/EC-18-0546 |
Ejemplares similares
-
The evolving place of incretin-based therapies in type 2 diabetes
por: Gallwitz, Baptist
Publicado: (2010) -
Role of incretin‐based therapy in hospitalized patients with type 2 diabetes
por: Gracia‐Ramos, Abraham Edgar
Publicado: (2019) -
Incretin-based therapies
por: Stonehouse, Anthony H, et al.
Publicado: (2012) -
Cardiovascular Effect of Incretin-Based Therapy in Patients with Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis
por: Kim, Je-Yon, et al.
Publicado: (2016) -
Incretin hormones and type 2 diabetes
por: Nauck, Michael A., et al.
Publicado: (2023)